Expertise in
3
conditions

Peter Kampmann

Rigshospitalet
Copenhagen, DK 
Expertise in
3
conditions
Rigshospitalet
Copenhagen, DK 

Overview

Peter Kampmann practices practicing medicine in Copenhagen, Denmark.

Mr. Kampmann is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Hemophilia B, Blood Clots, Hemophilia A, Thrombocytopenia, and Prostatic Artery Embolization.

He is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 1 clinical trial.

Gender

Male

Locations

Rigshospitalet
Copenhagen, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3

26 Total Publications

Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial.
Etranacogene dezaparvovec in people with hemophilia B and without adeno-associated virus serotype 5 neutralizing antibodies: a 4-year subgroup analysis of the Health Outcomes with Padua Gene; Evaluation in Hemophilia B (HOPE-B) trial.
Journal: Research and practice in thrombosis and haemostasis
Published: August 31, 2025

Frequently Asked Questions about Peter Kampmann

Is Peter Kampmann a top-rated expert for Hemophilia B?

MediFind is an objective health platform that identifies experts based on real-world data. Peter Kampmann is classified as an Elite expert for Hemophilia B, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Peter Kampmann participate in research or clinical trials?

Yes. Peter Kampmann has published 26 articles and abstracts on conditions like Hemophilia B. You can view a list of Peter Kampmann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kampmann's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile